Full Text Full Text (PDF) Correction Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Articles by Laje, G. Articles by McMahon, F. J. PubMed Citation Articles by Laje, G. Articles by McMahon, F. J. Depression Antidepressants Related Article

Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results

Dr. Laje and Dr. McMahon are affiliated with the Genetic Basis of Mood and Anxiety Disorders Unit, National Institute of Mental Health, 35 Convent Dr., MSC:3719, Bldg. 35/1A207, Bethesda, MD 20892 (e-mail: gonzalo.laje{at}nih.gov). Dr. Perlis is with the Department of Psychiatry, Massachusetts General Hospital, Boston. Dr. Rush is with the Duke-National University of Singapore. This article is part of a special section on the STAR*D trial (Sequenced Treatment Alternatives to Relieve Depression) and the implications of its findings for practice and policy. Grayson S. Norquist, M.D., M.S.P.H., served as guest editor of the special section.

Several lines of evidence support an important genetic contribution to the wide individual variation in therapeutic response to antidepressant medications. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study provided the largest cohort assembled to date of DNA from patients with nonpsychotic major depressive disorder, uniformly treated with citalopram and followed prospectively for up to 12 weeks. This pivotal study changed the face of pharmacogenetics research by increasing the sample size by an order of magnitude as well as by providing detailed prospective information about antidepressant response and tolerability. Several groups have identified markers in genes and tested the replication of previous findings of genes associated with outcome and side effects of antidepressant treatment. Variants in HTR2A, GRIK4, and KCNK2 were associated with citalopram treatment outcome. Replication was achieved in markers in the FKBP5 gene. Other findings in PDE11A and BDNF were not successfully replicated, and reports of potential confounders in previous associations with serotonin transporter variation (SLC6A4) were identified. Polymorphisms in pharmacokinetic genes involved in metabolism and transmembrane transport were also not associated with antidepressant response. Adverse events were also tested. Treatment-emergent suicidal ideation was associated with GRIK2, GRIA3, PAPLN, IL28RA, and CREB1. Sexual dysfunction was linked with variation in GRIN3A, GRIA1 GRIA3, and GRIK2. Reported and future findings of pharmacogenetics studies in STAR*D could help elucidate pathways involved in major depression and those pertinent to antidepressant outcome and side effects. Replication of these findings in independent samples could lead to the development of new treatments and to optimization of available treatments.

Related Article:

November: This Month's Highlights
Psychiatr Serv 2009 60: 1425. [Full Text] [PDF]

This article has been cited by other articles:

				G. S. Norquist Introduction to the STAR*D Special Section Psychiatr Serv, November 1, 2009; 60(11): 1437 - 1438. [Full Text] [PDF]

				A. Little, R. A. Hansen, G. Gartlehner, and C. Gray Impact of the STAR*D Trial From the Perspective of the Payer Psychiatr Serv, November 1, 2009; 60(11): 1463 - 1465. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2009 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us